ClinicalTrials.gg
CompletedNCT02406872Updated Dec 31, 2015

A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations

A Phase 2 interventional study of Remimazolam Tosilate and Propofol in General Anesthesia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-12-31.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as an intravenous general anaesthetic drug in operations and to determine its efficacy and safety profile comparing to propofol.

Read the detailed description

This is an multi-center,double-blinded,parallel and control study using Remimazolam or propofol for anesthesia in operations.Subjects are randomized to different treatment groups (including 3 for Remimazolam Tosilate and 1 for propofol) and anaesthetics are pumped contimuously into bodies.Analgesics and muscle relaxants are permitted during operations.Efficacy,safety and pharmacokinetic/pharmacodynamic profiles of Remimazolam Tosilate are to be evaluated.

02

Conditions studied

  • General Anesthesia
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects aged 18-60 years;
  • intending to have non-emergency operations;
  • ASA( ) I or II;
  • 18 kg/m²\<(Body Mass Index)\<30 kg/m².

Exclusion criteria

Exclusion Criteria:

  • people with to general anaesthesia;
  • one or more of the laboratory findings fall out of the limitations for this study(,,,etc.);
  • history of recent use of narcotics,analgesics,anaesthetics and benzodiazepine hypnotics;
  • history of severe cardiovascular disease;
  • uncontrolled blood glucose level;
  • cerebral disease or mental disorder;
  • allergic to drugs used in the study;
  • pregnant women or those in lactation period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Remimazolam Tosilate 1

    IV pumping of Remimazolam Tosilate at 6mg/kg/h for anesthesia induction

    Drug: Remimazolam Tosilate

  • Experimental
    Remimazolam Tosilate 2

    intravenous pumping of Remimazolam Tosilate at 12mg/kg/h for anesthesia induction

    Drug: Remimazolam Tosilate

  • Experimental
    Remimazolam Tosilate 3

    intravenous pumping of Remimazolam Tosilate at 18mg/kg/h for anesthesia induction

    Drug: Remimazolam Tosilate

  • Active comparator
    Propofol

    single IV bolus of Propofol at 2.0-2.5mg/kg for anesthesia induction

    Drug: Propofol

Interventions

06

What researchers measure

Primary outcomes

  1. successful anaesthesia rate as measured by the proportion of subjects who experienced succesful anesthesia during operations

    Time frame: an average of 3 hours (immediately after opaerations)

Secondary outcomes

  1. bispectral index(BIS) during anaesthesia as measured by bispectral index machine

    Time frame: every 5 minutes

  2. recovery time as measured by time

    Time frame: an average of 3 hours (after cessation of anesthetics pumping)

  3. induction time as measured by time

    Time frame: 1-10 minutes (from the begining of anesthetics)

Other outcomes

  1. rate of improper-depths sedation as measured by the proportion of subjects who experienced too-deep or too-shallow anesthesia during operations

    Time frame: an average of 3 hours (after anesthesia)

  2. rate of hypotention as measured by the proportion of subjects who experienced hypotention during operations

    Time frame: an average of 3 hours (after anesthesia)

  3. rate of hyoxemia as measured by the proportion of subjects who experienced hyoxemia during operations

    Time frame: an average of 3 hours (after anesthesia)

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Peking, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2015
First posted
Apr 2, 2015
Start
Dec 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Dec 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02406872
Responsible party
Sponsor
First posted
Apr 2, 2015
Start date
Dec 2014
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Dec 31, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion